Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Boehringer Ingelheim to Evaluate Afatinib in Combination with PD-1 Inhibitor Pembrolizumab in New Tr

americanpharmaceuticalreviewFebruary 10, 2017

Tag: Boehringer Ingelheim , pembrolizumab

PharmaSources Customer Service